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As the leading cause of hospital readmission, heart fail-ure is a significant burden on healthcare systems.1 In the 
United States alone, >$39 billion was spent on the care of 
patients with heart failure in 2010, with the majority spent on 
inpatient care.2 The US Centers for Medicare and Medicaid 
Services publicly reports rates of readmission within 30 days 
of discharge from a heart failure hospitalization, and 30-day 
readmission rates are likely to be bundled to reimbursement 
for the index hospitalization. Given the focus on 30-day 
readmission by payers and policy makers, there is an urgent 
need to understand the role of length of stay and to develop 
treatments and management strategies that reduce a patient’s 
risk of early readmission and mortality.
Clinical Perspective on p 732
Few strategies have proven efficacious in significantly 
reducing 30-day readmission rates.3–6 Similarly, few clinical 
factors have been shown to reliably identify patients at high 
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Background—Hospital readmission is an important clinical outcome of patients with heart failure. Its relation to length of 
stay for the initial hospitalization is not clear.
Methods and Results—We used hierarchical modeling of data from a clinical trial to examine variations in length of 
stay across countries and across hospitals in the United States and its association with readmission within 30 days of 
randomization. Main outcomes included associations between country-level length of stay and readmission rates, after 
adjustment for patient-level case mix; and associations between length of stay and readmission rates across sites in the 
United States. Across 27 countries with 389 sites and 6848 patients, mean length of stay ranged from 4.9 to 14.6 days 
(6.1 days in the United States). Rates of all-cause readmission ranged from 2.5% to 25.0% (17.8% in the United States). 
There was an inverse correlation between country-level mean length of stay and readmission (r=–0.52; P<0.01). After 
multivariable adjustment, each additional inpatient day across countries was associated with significantly lower risk of 
all-cause readmission (odds ratio, 0.86; 95% confidence interval, 0.75–0.98; P=0.02) and heart failure readmission (odds 
ratio, 0.79; 95% confidence interval, 0.69–0.99; P=0.03). Similar trends were observed across US study sites concerning 
readmission for any cause (odds ratio, 0.92; 95% confidence interval, 0.85–1.00; P=0.06) and readmission for heart 
failure (odds ratio, 0.90; 95% confidence interval, 0.80–1.01; P=0.07). Across countries and across US sites, longer 
median length of stay was independently associated with lower risk of readmission.
Conclusions—Countries with longer length of stay for heart failure hospitalizations had significantly lower rates of 
readmission within 30 days of randomization. These findings may have implications for developing strategies to prevent 
readmission, defining quality measures, and designing clinical trials in acute heart failure.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00475852.   
(Circ Heart Fail. 2013;6:727-732.)
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risk for early readmission. Some processes of care, such as 
early follow-up, are associated with modestly lower hospital-
level rates of early readmission.7 In myocardial infarction, 
country-level length of stay has been shown to be inversely 
related to early readmission.8 However, the impact of length of 
stay on readmission rates for patients with heart failure, who 
often have multiple comorbid conditions and are readmitted 
for causes other than heart failure, is less clear.
We examined length of stay and readmission rates in 
the Acute Study of Clinical Effectiveness of Nesiritide in 
Decompensated Heart Failure (ASCEND-HF). We examined 
country-level variations in length of stay for patients with 
heart failure, the relationship between country-level length of 
stay and early readmission, and the relationship between site-
level length of stay and early readmission in the United States.
Methods
Data Source
ASCEND-HF was a multinational, double-blind, placebo-controlled 
study designed to evaluate the effectiveness and safety of nesiritide in 
addition to standard care among patients with acute decompensated 
heart failure. Participants were randomly assigned to a study group 
within 48 hours of hospitalization. Detailed inclusion and exclusion 
criteria have been described previously.9 The 2 primary end points 
were a composite end point of heart failure readmission or all-cause 
mortality up to 30 days after randomization and the change in dysp-
nea at 6 and 24 hours after study drug initiation.
Patient Characteristics and Outcome Data
Data on patient characteristics were collected at during the baseline 
hospitalization through the trial case report form. The case report 
form also collected information on all readmissions within 30 days 
of randomization. If a patient was readmitted, study staff documented 
the admission and discharge dates and the primary reason for the re-
admission. Hospitalization was defined as a stay of >24 hours from 
admission to discharge. For patients who were transferred to a second 
hospital, we combined the hospitalization days from both hospitals to 
determine their total inpatient length of stay.
Statistical Analysis
Consistent with the main trial analyses of treatment efficacy, we lim-
ited our analysis to the modified intention-to-treat population. Similar 
to publicly reported readmission rates for Medicare beneficiaries, we 
included patients who died after discharge but excluded those who 
died before discharge or were still hospitalized at 30 days. For statis-
tical stability, we also excluded countries that enrolled <20 patients. 
We used means, SDs, medians, and proportions, as appropriate, to de-
scribe the variables of interest. We calculated the correlation between 
length of stay and readmission using Pearson correlation coefficient 
analysis. To account for the hierarchical nature of the data, in which 
patients were clustered within sites and sites were clustered within 
countries, we used a 3-level logistic regression model (ie, country, 
site, patient) to evaluate the relationships between country-level mean 
lengths of stay for the index admission and country-level readmission 
rates within 30 days after randomization. We used a 2-level logis-
tic regression model to evaluate the relationships between site-level 
mean lengths of stay for the index admission and readmission rates 
among sites in the United States. We included 2 random intercepts 
accounting for the clustering effects of sites and countries in the all-
country analysis and 1 random intercept accounting for the cluster-
ing effect of different sites in the US analysis. Consistent with other 
post hoc analyses investigating postdischarge outcomes in ASCEND-
HF,10 we included the following patient-level variables in each model: 
age, history of cerebrovascular disease, history of chronic obstructive 
pulmonary disease, history of depression, heart failure readmission 
1 year before the index admission, severity of baseline dyspnea, ele-
vated jugular venous pressure, systolic blood pressure, sodium, blood 
urea nitrogen, and creatinine. To account for differential periods of 
time when patients with shorter and longer lengths of stay were at 
risk for readmission, we included a covariate representing days from 
the index discharge to death, dropout, or 30 after randomization in the 
logistic models. We performed the analysis across all countries and 
across US sites only, given US policy interests and public reporting of 
hospital-level 30-day readmission rates for patients with heart failure. 
We evaluated rates of readmission for any cause and for heart failure.
We used SAS version 9.2 (SAS Institute Inc, Cary, NC) for all 
analyses. The Institutional Review Board of the Duke University 
Health System approved this study.
Results
ASCEND-HF enrolled 7141 participants at 398 sites in 30 
countries in North America, Latin America, Europe, and Asia 
between May 2007 and August 2010. The modified intention-
to-treat analysis of the 7007 patients who received the study 
drug revealed no significant findings concerning the primary 
end points. There were 9.4% of patients in the nesiritide group 
and 10.1% of patients in the placebo group who experienced 
hospital readmission because of heart failure or who died from 
any cause within 30 days (P=0.31). There were no significant 
differences in 30-day or 180-day mortality between the groups.
After excluding countries that enrolled fewer than 20 patients 
(n=25) and patients who died before discharge from the index 
hospitalization (n=151) or were still hospitalized at 30 days 
(n=141), we derived a final study population of 6824 patients 
from 389 sites in 27 countries. Of these, 779 (11.4%) were read-
mitted for any cause within 30 days, and 366 (5.4%) were read-
mitted for heart failure. Eighty-one patients (1.2%) died after 
discharge from the index hospitalization and had no readmis-
sion within 30 days. Of the 2684 patients in the United States, 
477 (17.8%) patients were readmitted for any cause within 30 
days and 236 (8.8%) patients were readmitted for heart failure.
Table 1 shows the baseline characteristics of the study pop-
ulation. Patients readmitted within 30 days were more likely 
to have been hospitalized for heart failure in the year before 
admission and to have comorbid conditions. Patients read-
mitted within 30 days were more likely to have lower blood 
pressure and hemoglobin level, and higher B-type natriuretic 
peptide, blood urea nitrogen, and creatinine levels.
Table 2 shows country-level estimates of mean length of 
stay and rates of readmission within 30 days of randomiza-
tion. Mean age ranged from 57.7 to 75.9 years. Systolic blood 
pressure ranged from 117.8 to 133.5 mm Hg. Heart rate ranged 
from 75.2 to 91.1 beats per minute. Country-level mean length 
of stay ranged from 4.9 to 14.6 days. Mean length of stay 
among US sites was 6.1 days. Mean country-level all-cause 
readmission rates ranged from 2.5% to 25.0%. The readmis-
sion rate among US sites was 17.8%. Figure 1 shows the 
inverse correlation between country-level mean length of stay 
and readmission rates (r=–0.52; P<0.01). To explore the pos-
sible nonlinear relationship between length of stay and read-
mission, we added a quadratic term of mean length of stay in 
all models, and it was not significant across countries (P=0.25) 
or across US sites (P=0.45). As shown in Figure 2, after mul-
tivariable adjustment, each 1-day increase in the mean length 
of stay across countries was independently associated with a 
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lower risk of all-cause readmission (odds ratio [OR], 0.86; 
95% confidence interval [CI], 0.75–0.98; P=0.02) and heart 
failure readmission (OR, 0.79; 95% CI, 0.69–0.99; P=0.03). 
Similar trends were observed when we examined mean length 
of stay across US study sites concerning readmission for any 
cause (OR, 0.92; 95% CI, 0.85–1.00; P=0.06) and readmis-
sion for heart failure (OR, 0.90; 95% CI, 0.80–1.01; P=0.07). 
In sensitivity analyses, we substituted the mean length of stay 
with median length of stay. In countries with longer median 
length of stay, patients experienced a lower risk of all-cause 
readmission (OR, 0.86; 95% CI, 0.76–0.97; P=0.02) and heart 
failure readmission (OR, 0.83; 95% CI, 0.69–0.99; P=0.04). 
Similarly, among US sites, median length of stay was asso-
ciated with a lower risk of all-cause readmission (OR, 0.91; 
95% CI, 0.83–1.00; P=0.04) and heart failure readmission 
(OR, 0.86; 95% CI, 0.75–0.98; P=0.02).
Discussion
In this analysis of data from the largest multinational trial 
to date among patients with acute decompensated heart fail-
ure, we found that mean length of stay and early readmission 
rates varied considerably across countries. After adjustment 
for patient characteristics, country-level variability in sample 
size, and days at risk for readmission, longer length of stay 
was associated with a lower risk of early readmission. Using 
median length of stay, we observed significant relationships 
across countries and across US sites.
The frequency of hospitalizations among patients with 
heart failure constitutes a major challenge for aging popula-
tions in healthcare systems with significant vulnerabilities in 
transitional care. Risk-adjusted readmission rates for US hos-
pitals are reported publically to incentivize local practices for 
improving care. In addition, bundled payments for US hos-
pitals are being evaluated and payment reductions for those 
with high readmission rates for heart failure have been imple-
mented.11,12 In response to these payment reforms, hospitals 
are joining national quality-improvement campaigns, such as 
Hospital to Home and Target: HF, to share best practices.13,14 
However, few treatments of patients with acute decompen-
sated heart failure have been found to effective in randomized 
trials, and fewer have been evaluated using an end point of 
30-day all-cause readmission. Early postdischarge follow-up 
Table 1. Baseline Characteristics of the Study Population
Variables
Not Readmitted Within 30 Days 
(n=6045)*
Readmitted Within 30 Days 
(n=779)*  P Value
Age, median (IQR), y 66.0 (56.0–76.0) 68.0 (56.0–77.0) 0.14
Female sex, % 34.0 34.4 0.83
Race, n (%) <0.01
  Asian 1590 (26.3) 112 (14.4)
  Black 883 (14.6) 172 (22.1)
  White 3297 (54.5) 473 (60.7)
  Other 274 (4.5) 22 (2.8)
Comorbid conditions, n (%)
  Atrial fibrillation or flutter 2193 (36.3) 345 (44.3) <0.01
  Chronic respiratory disease 920 (15.2) 193 (24.8) <0.01
  Coronary artery disease 3249 (53.8) 479 (61.2) <0.01
  Depression 434 (7.2) 105 (13.5) <0.01
  Diabetes mellitus 2509 (41.5) 390 (50.1) <0.01
  Heart failure 1 y before admission 2204 (36.5) 422 (54.2) <0.01
  Hypertension 4334 (71.7) 605 (77.7) <0.01
  Myocardial infarction 2073 (34.3) 301 (38.7) 0.02
Clinical values, median (IQR)
  Blood pressure, mm Hg
   Systolic 124.0 (110.0–140.0) 121.0 (110.0–137.0) <0.01
   Diastolic 75.0 (67.0–84.0) 72.0 (64.0–82.0) <0.01
  Blood urea nitrogen, mg/dL 25.0 (17.7–37.4) 28.1 (19.0–40.1) <0.01
  Creatinine, μmol/L 106.1 (88.4–135.0) 114.9 (96.4–150.3) <0.01
  Ejection fraction, % 30.0 (20.0–36.0) 28.0 (20.0–39.0) 0.78
  Heart rate, beats per minute 82.0 (72.0–95.0) 81.0 (70.0–93.0) 0.11
   BNP 958.0 (526.0–1801.0) 1140.0 (634.0–2065.2) <0.01
   N-terminal pro-BNP 4277.6 (2002.1–8704.9) 5467.8 (2759.1–10841.5) <0.01
  Hemoglobin, g/dL 12.7 (11.4–14.1) 12.4 (11.0–13.6) <0.01
  Sodium, mmol/L 139.0 (136.0–141.0) 138.7 (136.0–141.0) 0.11
BNP indicates B-type natriuretic peptide; and IQR, interquartile range.
*Ascertained during 30 days from randomization.
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is associated with lower readmission rates,7 but it is unclear 
whether extending inpatient stays has a similar influence. 
Consistent with observations in other disease states,8,15 our 
findings provide evidence that shorter lengths of stay have an 
adverse impact on short-term outcomes. Our findings from 
this international data set are also consistent with trends noted 
among Medicare beneficiaries in the United States.16 This 
highlights the importance of understanding country-level dif-
ferences in length of stay within a multinational trial when 
determining the relevance of results for a specific population.
Since 1984, when the current reimbursement model was 
introduced in the United States, there have been strong incen-
tives to reduce lengths of stay to maximize hospital profit-
ability. The consequent reduction in hospital lengths of stay 
has been accompanied by increases in postdischarge readmis-
sion rates,17 which may have resulted in greater overall costs 
among patients with heart failure. In comparing the average 
spending for a heart failure hospitalization and the 30 days 
after discharge, postdischarge care and 30-day readmissions 
account for the difference between high-resource-use and low-
resource-use hospitals, whereas index hospitalization costs 
are similar.11 Therefore, identifying the appropriate length of 
stay for patients and efficient transitions of care to ambula-
tory settings are critical components of providing not only 
patient-centered care but also more cost-effective care. As a 
result, provider responsibilities during a hospitalization for 
heart failure can extend beyond ensuring clinical stability to 
include educating patients and families, reconciling inpatient 
and outpatient medication regimens, improving discharge 
planning, initiating multidisciplinary interventions, ensuring 
timely follow-up with outpatient providers, coordinating care 
with ambulatory services, and potentially using remote moni-
toring strategies.7,18–23 Using an additional inpatient day as an 
intervention, allowing providers not only to ensure clinical 
stability but also to use locally available strategies for care 
coordination may warrant further investigation. Defining 
parameters for patient stability and optimal risk thresholds for 
discharge can help guide both clinical judgment and policy 
making toward more effective transitions of care.
With the trend toward globalization in clinical research and 
international differences in patterns of care,24–26 it is important 
to identify country-level factors that may confound a treat-
ment’s effect on clinical end points. In this study, length of 
stay as a country-level factor was significantly correlated with 
early readmission. Other post hoc analyses have demonstrated 
that heterogeneity in trial results may be related in part to 
underlying country-level differences. In the Platelet Inhibition 
and Patient Outcomes (PLATO) trial, for example, aspirin 
Table 2. Length of Stay and 30-Day All-Cause Readmission 
Rates Among Patients Discharged Alive With Length of Stay 
<30 Days
Countries Patients, n
Length of Stay,  
Mean (SD), d
Readmission  
Rate,* %
Correlation
r P Value
Argentina 209 6.6 (3.6) 11.0 –0.06 0.35
Australia 32 8.6 (4.7) 15.6 –0.02 0.93
Brazil 134 9.2 (5.2) 7.5 0.02 0.81
Bulgaria 65 7.0 (2.5) 6.2 0.11 0.40
Canada 445 9.3 (5.6) 14.2 –0.07 0.15
Chile 47 8.3 (4.3) 10.6 –0.07 0.63
China 293 11.9 (5.4) 4.4 0.07 0.20
Columbia 30 8.0 (3.8) 16.7 0.20 0.30
France 91 9.2 (4.1) 13.2 –0.14 0.20
Greece 45 7.8 (5.0) 6.7 –0.02 0.18
India 973 4.9 (2.4) 3.8 0.05 0.12
Israel 75 5.2 (3.1) 18.7 0.09 0.42
Italy 64 10.1 (5.2) 4.7 –0.12 0.35
Lithuania 88 12.2 (5.4) 3.4 –0.16 0.14
Malaysia 73 6.6 (3.4) 17.8 0.13 0.29
Mexico 214 5.4 (2.6) 3.3 0.02 0.82
Netherlands 130 9.1 (5.0) 3.1 –0.09 0.30
Norway 51 9.7 (6.8) 3.9 0.02 0.87
Poland 259 9.1 (5.1) 8.5 –0.01 0.90
Romania 47 10.5 (3.0) 4.3 0.22 0.15
Russia 278 14.6 (5.1) 2.5 0.08 0.21
Singapore 52 5.3 (2.6) 25.0 0.03 0.83
South Korea 145 8.9 (4.3) 5.5 –0.06 0.49
Taiwan 71 8.3 (5.8) 19.7 0.02 0.87
Thailand 46 6.4 (3.4) 10.9 –0.12 0.48
Ukraine 183 10.9 (4.3) 2.7 0.19 0.01
United States 2684 6.1 (4.0) 17.8 –0.01 0.55
*Ascertained during 30 days from randomization.
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Figure 1. Country-level relationship of early all-
cause readmission with mean length of stay for 
index heart failure hospitalizations. Each circle 
represents a country that enrolled a patient in the 
Acute Study of Clinical Effectiveness of Nesiritide in 
Decompensated Heart Failure (ASCEND-HF). The 
size of each circle is proportional to the country-
level sample size.
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maintenance dose may have explained regional differences in 
the efficacy of ticagrelor among patients with acute coronary 
syndrome.27 Regional variations in the use of evidence-based 
therapies may have also influenced treatment effects in multi-
national heart failure trials.28
Our study has some limitations. First, despite adjustment 
for multiple patient-level covariates in the multilevel models, 
residual or unmeasured confounding may remain. Second, 
early readmission among US sites was lower in this study 
than found in Medicare data, likely because of differences 
in the age of the study population resulting from selection of 
patients into a clinical trial. Sites participating in a clinical 
trial may similarly be subject to selection bias. They may pos-
sess resources and infrastructure that distinguish them from 
hospitals that care for patients with heart failure but do not 
participate in clinical trials. Third, readmissions in this trial 
data set were ascertained over 30 days from randomization 
(median time from hospitalization to randomization in pla-
cebo arm, 15.7 hours), which may have led to lower readmis-
sion rates than the postdischarge rates reported for Medicare 
beneficiaries. Thus, the findings may not be generalizable to 
the Medicare heart failure population that is often the focus of 
readmission policies in the United States. Nevertheless, it is 
important that ASCEND-HF was not only the largest trial per-
formed among patients with acute decompensated heart fail-
ure but was also a pragmatic trial with few exclusion criteria.9
Conclusions
Patients treated in countries with longer lengths of stay for 
heart failure hospitalizations had significantly lower rates of 
readmission within 30 days of randomization. Findings were 
similar among sites in the United States, where each 1-day 
increase in the mean length of stay at the site level was inde-
pendently associated with a lower risk of all-cause and heart 
failure readmission. These findings may have implications for 
developing tactics to prevent readmission, defining quality 
measures, and designing clinical trials in acute heart failure.
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CLINICAL PERSPECTIVE
Heart failure (HF) is the leading cause of early readmissions in the United States and is a focus of payers and policy makers. 
Currently, there are few interventions and processes of care associated with reductions in 30-day readmission rates. In this 
analysis of data from the largest multinational trial to date among patients with acute decompensated heart failure, we found 
that patients treated in countries with longer lengths of stay for heart failure hospitalizations had significantly lower rates of 
early readmission. Among US sites, we found that each 1-day increase in the mean length of stay was independently associ-
ated with a lower risk of all-cause and heart failure readmission. Consistent with observations in other disease states, our 
findings provide evidence that shorter lengths of stay for HF patients are associated with less favorable outcomes in terms of 
this metric. Identifying the appropriate length of stay for patients and efficient transitions of care to ambulatory settings are 
critical components of providing not only patient-centered care but also more cost-effective care.
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